SCHEMBL3018947

SCHEMBL3018947

COc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4F)CC3)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.44
HSD17B10 Q99714 4/20 0.44
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
GPR6 P46095 2/20 0.40
LMNA P02545 5/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 3/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 2/20 0.39
PTPRB P23467 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
PKM P14618 2/20 0.37
TSHR P16473 1/20 0.37
PRKAA2 P54646 1/20 0.36
NMT1 P30419 1/20 0.36
AR P10275 1/20 0.35
CTSS P25774 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015886 0.92 GPR6 (0.41) MAPTHSD17B10USP2RECQLGPR6
SCHEMBL3003383 0.92 CTSS (0.45) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3007854 0.91 MAPT (0.43) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3011732 0.91 GPR6 (0.42) MAPTHSD17B10USP2RECQLGPR6
SCHEMBL3010968 0.89 GPR6 (0.38) MAPTGPR6LMNATP53SMN1; SMN2
SCHEMBL3014608 0.89 MAPT (0.51) MAPTHSD17B10USP2RECQLGPR6
SCHEMBL3014427 0.88 MAPT (0.45) MAPTHSD17B10USP2RECQLGPR6
SCHEMBL3016948 0.88 CTSS (0.37) MAPTGPR6LMNAALDH1A1SMN1; SMN2
SCHEMBL3004414 0.88 MAPT (0.42) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3010780 0.88 NAAA (0.41) MAPTGPR6LMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.